{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:45:27Z","timestamp":1792986327029,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["19ck0106340h0003"],"award-info":[{"award-number":["19ck0106340h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isocitrate dehydrogenase\u2013mutant astrocytoma without cyclin-dependent kinase inhibitor 2A\/B (CDKN2A\/B) homozygous deletion typically follows a slow clinical course. However, some cases show early progression on magnetic resonance imaging, and these characteristics remain under-reported. This study aimed to elucidate the characteristics of isocitrate dehydrogenase\u2013mutant astrocytoma showing early progression on magnetic resonance imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included 52 cases of primary astrocytoma, isocitrate dehydrogenase\u2013mutant, Central Nervous System (CNS) 5 World Health Organization grade 2\u20133 according to the World Health Organization 2021 classification. Patients underwent surgery followed by radiation therapy and\/or chemotherapy at our institution from 2006 to 2019. Progression-free survival and overall survival were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 24 and 28 grade 2 and grade 3 astrocytomas, respectively. The median patient age was 38\u00a0years. Forty-three patients underwent radiotherapy. Progression was diagnosed by magnetic resonance imaging in 22 patients with initial radiotherapy. Thirteen of the 22 patients underwent surgery, and seven of the 13 patients received surgery within 24\u00a0months of the initial radiotherapy. Histopathologically, radiation necrosis was confirmed in four of these seven patients (57.1%). The true progression-free survival rate, excluding radiation necrosis, at 2\u00a0years after surgery was 91.3% for grade 2 astrocytoma and 88.5% for grade 3 astrocytoma. The 5-year overall survival rate was 85.7% for grade 2 tumours and 76.4% for grade 3 tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Radiation necrosis should be considered in cases showing early progression of isocitrate dehydrogenase\u2013mutant astrocytoma, and a second surgery should be performed to confirm true recurrence or radiation necrosis. Astrocytomas with telomerase reverse-transcriptase promoter mutations may relapse relatively early and should be followed up with caution.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae151","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T09:57:31Z","timestamp":1733911051000},"page":"106-112","source":"Crossref","is-referenced-by-count":1,"title":["Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)\u2013mutant astrocytoma may indicate radiation necrosis"],"prefix":"10.1093","volume":"55","author":[{"given":"Yukie","family":"Ozeki","sequence":"first","affiliation":[{"name":"Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]},{"name":"Department of Neurosurgery, Saitama Cancer Center , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Honda-Kitahara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]},{"name":"Division of Brain Tumor Translational Research, National Cancer Center Research Institute , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]},{"name":"Department of Neurosurgery, Tokai University School of Medicine , Isehara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8031-4306","authenticated-orcid":false,"given":"Makoto","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Miyakita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miu","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Hosoya","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaishi","family":"Satomi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University Faculty of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-624X","authenticated-orcid":false,"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-3370","authenticated-orcid":false,"given":"Yuko","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kyorin University Faculty of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Brain Tumor Translational Research, National Cancer Center Research Institute , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenkichi","family":"Masutomi","sequence":"additional","affiliation":[{"name":"Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Division of Cancer Stem Cell, National Cancer Center Research Institute , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Juntendo University Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6006","authenticated-orcid":false,"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025020413014293300_ref1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz124","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro-Oncology"},{"key":"2025020413014293300_ref2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2025020413014293300_ref3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-017-0443-7","article-title":"Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery","volume":"5","author":"Cimino","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"2025020413014293300_ref4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/NEN.0000000000000188","article-title":"CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization grades II-III) astrocytomas","volume":"74","author":"Reis","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025020413014293300_ref5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2025020413014293300_ref6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bpa.12801","article-title":"IDH mutant lower grade (WHO grades II\/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations","volume":"30","author":"Yang","year":"2020","journal-title":"Brain Pathol"},{"key":"2025020413014293300_ref7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"2025020413014293300_ref8","first-page":"9","article-title":"2017","volume":"57","author":"Brain Tumor Registry of Japan","year":"2005\u20132008","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2025020413014293300_ref9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00401-016-1611-8","article-title":"Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort","volume":"132","author":"Tabouret","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2025020413014293300_ref10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"Bent","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025020413014293300_ref11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/nos307","article-title":"Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies","volume":"15","author":"Verma","year":"2013","journal-title":"Neuro-Oncology"},{"key":"2025020413014293300_ref12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-016-0351-2","article-title":"A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas","volume":"4","author":"Arita","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"2025020413014293300_ref13","doi-asserted-by":"publisher","first-page":"21190","DOI":"10.18632\/oncotarget.8498","article-title":"Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas","volume":"7","author":"Duregon","year":"2016","journal-title":"Oncotarget"},{"key":"2025020413014293300_ref14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathol"},{"key":"2025020413014293300_ref15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/jnen\/nlz082","article-title":"Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma","volume":"78","author":"Yoda","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025020413014293300_ref16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1148\/radiology.217.2.r00nv36377","article-title":"Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment","volume":"217","author":"Kumar","year":"2000","journal-title":"Radiology"},{"key":"2025020413014293300_ref17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ijrobp.2009.02.035","article-title":"Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment","volume":"74","author":"Wilson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025020413014293300_ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6828396","article-title":"Radiation necrosis, Pseudoprogression, Pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas","volume":"2018","author":"Zikou","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"2025020413014293300_ref19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s00259-007-0661-5","article-title":"Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence","volume":"35","author":"G\u00f3mez-R\u00edo","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025020413014293300_ref20","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3174\/ajnr.A6685","article-title":"Diagnostic performance of PET and perfusion-weighted imaging in differentiating tumor recurrence or progression from radiation necrosis in Posttreatment gliomas: a review of literature","volume":"41","author":"Soni","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"2025020413014293300_ref21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00259-017-3916-9","article-title":"(11)C-MET PET\/MRI for detection of recurrent glioma","volume":"45","author":"Deuschl","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025020413014293300_ref22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.clineuro.2010.06.005","article-title":"Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI","volume":"112","author":"Kim","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"2025020413014293300_ref23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2176\/nmc.oa2013-0117","article-title":"Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis","volume":"54","author":"Takenaka","year":"2014","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2025020413014293300_ref24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2967\/jnumed.107.048082","article-title":"Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy","volume":"49","author":"Terakawa","year":"2008","journal-title":"J Nucl Med"},{"key":"2025020413014293300_ref25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3174\/ajnr.A3324","article-title":"Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis","volume":"34","author":"Nihashi","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"2025020413014293300_ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.671867","article-title":"Diagnostic accuracy of PET for differentiating true glioma progression from post treatment-related changes: a systematic review and meta-analysis","volume":"12","author":"Cui","year":"2021","journal-title":"Front Neurol"},{"key":"2025020413014293300_ref27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0038-1636430","article-title":"Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing","volume":"38","author":"Deimling","year":"2018","journal-title":"Semin Neurol"},{"key":"2025020413014293300_ref28","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/bjc.2014.538","article-title":"TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations","volume":"111","author":"Labussi\u00e8re","year":"2014","journal-title":"Br J Cancer"},{"key":"2025020413014293300_ref29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ccell.2019.03.009","article-title":"Doomed from the TERT? A two-stage model of tumorigenesis in IDH-wild-type glioblastoma","volume":"35","author":"Stead","year":"2019","journal-title":"Cancer Cell"},{"key":"2025020413014293300_ref30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ijc.30735","article-title":"Altered TERT promoter and other genomic regulatory elements: occurrence and impact","volume":"141","author":"Heidenreich","year":"2017","journal-title":"Int J Cancer"},{"key":"2025020413014293300_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa025","article-title":"TERT, a promoter of CNS malignancies","volume":"2","author":"Patel","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2025020413014293300_ref32","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research N","year":"2015","journal-title":"N Engl J Med"},{"key":"2025020413014293300_ref33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00401-015-1409-0","article-title":"Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups","volume":"129","author":"Weller","year":"2015","journal-title":"Acta Neuropathol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/106\/61030073\/hyae151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/106\/61030073\/hyae151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:02:00Z","timestamp":1738674120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/2\/106\/7920851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae151","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,11]]}}}